VEGFA and diabetic macular edema: Anti-VEGF agents play a key role in the management of different retinal conditions, such as wet AMD, diabetic macular edema, and retinal vein occlusion.[10,11,12] As most of these patients need multiple anti-VEGF injections, these drugs incur high individual, medical, and societal costs.[13] By decreasing the cost of therapy, the economic burden on the individual patients, their families, and society will be reduced.